DL-Fluorocitric acid barium

Cat. No.: HY-W021450A: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

DL-Fluorocitric acid barium is a glial cell metabolic inhibitor. DL-Fluorocitric acid barium inhibits mechanical hyperalgesia induced by subcutaneous injection of complete Freund's adjuvant in rats. DL-Fluorocitric acid barium inhibits nociceptive behaviors induced by Histamine (HY-B1204) in mice and blocks the phosphorylation of the NMDA receptor NR1 subunit in the lumbar spinal cord of mice. DL-Fluorocitric acid (barium) can be used in the research of mechanical hyperalgesia and nociceptive pain.

For research use only. We do not sell to patients.

DL-Fluorocitric acid barium Chemical Structure

CAS No. : 100929-81-5

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	Get quote
200 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vivo

DL-Fluorocitric acid barium (0.01-1 nmol; intrathecal injection; single administration) dose-dependently inhibits complete Freund's adjuvant (CFA)-induced mechanical hyperalgesia in rats^[1].
DL-Fluorocitric acid barium (10-40 pmol; intrathecal injection; single administration) dose-dependently inhibits histamine (HY-B1204)-induced nociceptive behaviors in mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley (adult male, 190-220 g, inflammatory pain induced by subcutaneous CFA injection into left hind-paw)^[1]
Dosage:	0.01 nmol; 0.1 nmol; 1 nmol; 0.01 nmol (co-administered with 1 nmol LY341495)
Administration:	i.t.; single dose; 10 min pre-CFA
Result:	Increased paw withdrawal mechanical threshold to 9.50 g at 0.01 nmol. Increased paw withdrawal mechanical threshold to 16.00 g at 0.1 nmol. Increased paw withdrawal mechanical threshold to 54.33 g at 1 nmol. Increased paw withdrawal mechanical threshold to 44.2 g at 0.01 nmol co-administered with 1 nmol LY341495 (HY-70059), with a percentage maximal effect (%MPE) of 89.23%.

Animal Model:	ddY (male, 22-25 g)^[2]
Dosage:	10 pmol; 20 pmol; 40 pmol
Administration:	i.t.; 1 hour before histamine administration
Result:	Dose-dependently suppressed histamine-induced nociceptive behaviors. Completely eliminated histamine-induced nociceptive behaviors at 40 pmol dose. Significantly suppressed the histamine-induced increase in phosphorylated NR1 subunits of NMDA receptors in the dorsal lumbar spinal cord (P < 0.01) at 40 pmol dose.

Molecular Weight

416.10

Formula

C₆H₇FO₇.3/2Ba

CAS No.

100929-81-5

Appearance

Solid

Color

White to off-white

SMILES

OC(CC(O)=O)(C(O)=O)C(F)C(O)=O.[1.5].[Ba]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Purity & Documentation

Select Batch:

Data Sheet (274 KB) SDS (642 KB)

COA (251 KB)

Handling Instructions (2659 KB)

References

[1]. Zhang T, et al. Antinociceptive synergistic effect of spinal mGluR2/3 antagonist and glial cells inhibitor on peripheral inflammation-induced mechanical hypersensitivity. Brain Res Bull. 2009;79(3-4):219-223. [Content Brief]

[2]. Mizoguchi H, et al. Involvement of glial cells in the nociceptive behaviors induced by a high-dose of histamine administered intrathecally. Eur J Pharmacol. 2011;653(1-3):21-25. [Content Brief]